Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
暂无分享,去创建一个
[1] A. Partin,et al. Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. , 1989, The Journal of urology.
[2] J. Goméz,et al. Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.
[3] P. Walsh,et al. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended followup. , 1986, The Journal of urology.
[4] T. Stamey,et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.
[5] Galina Pizov,et al. Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.
[6] M. Benson,et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. , 1992, The Journal of urology.
[7] H C Aldape,et al. Prostate cancer: comparison of digital rectal examination and transrectal ultrasound for screening. , 1991, The Journal of urology.
[8] J. Epstein,et al. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. , 1991, The Journal of urology.
[9] P. Walsh,et al. Needle biopsy associated tumor tracking of adenocarcinoma of the prostate. , 1991, The Journal of urology.
[10] W. Cooner,et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.
[11] J. Oesterling,et al. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.
[12] A W Partin,et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.
[13] J. Trachtenberg,et al. Adenocarcinoma of the Prostate , 1988 .
[14] M. Terris,et al. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. , 1992, The Journal of urology.
[15] P. Walsh,et al. Evaluation of transrectal ultrasound in the early detection of prostate cancer. , 1989, The Journal of urology.
[16] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[17] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[18] J. Oesterling,et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.
[19] W. Whitmore. Natural history of low-stage prostatic cancer and the impact of early detection. , 1990, The Urologic clinics of North America.
[20] J. Oesterling,et al. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. , 1993, Urology.
[21] P. Walsh,et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.
[22] A. Pantuck,et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.